{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+A1", "query": { "intervention": "Cohort A1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 288, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+A1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T11:34:50.263Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05651932", "title": "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma", "Myeloma Multiple" ], "interventions": [ { "name": "Cohort A1 & A2: KTX-1001", "type": "DRUG" }, { "name": "Cohort B1 & B2: KTX-1001+Mezigdomide", "type": "DRUG" }, { "name": "Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)", "type": "DRUG" }, { "name": "Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-02-22", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 17, "location_summary": "San Francisco, California • Jacksonville, Florida • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651932" }, { "nct_id": "NCT06617546", "title": "SAD and MAD Study of FTX-101 in Healthy Male Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "FTX-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Find Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "MALE", "summary": "18 Years to 59 Years · Male only" }, "enrollment_count": 49, "start_date": "2024-10-14", "completion_date": "2025-04-17", "has_results": false, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06617546" }, { "nct_id": "NCT06292780", "title": "A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Systemic Light Chain Amyloidosis" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2024-08-07", "completion_date": "2035-02-20", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 8, "location_summary": "Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06292780" }, { "nct_id": "NCT01767454", "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2013-02-12", "completion_date": "2015-09-04", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767454" }, { "nct_id": "NCT04914897", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pleural Mesothelioma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "THOR-707", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-09-23", "completion_date": "2024-10-17", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04914897" }, { "nct_id": "NCT01966666", "title": "A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "TPI-287 2 mg/m2", "type": "DRUG" }, { "name": "TPI-287 6.3 mg/m2", "type": "DRUG" }, { "name": "TPI-287 20 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "50 Years to 82 Years" }, "enrollment_count": 29, "start_date": "2013-11", "completion_date": "2019-09", "has_results": false, "last_update_posted_date": "2020-04-14", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966666" }, { "nct_id": "NCT02789176", "title": "Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neonatal Seizures" ], "interventions": [ { "name": "Surveys", "type": "OTHER" }, { "name": "EEG", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Weeks", "maximum_age": "24 Months", "sex": "ALL", "summary": "0 Weeks to 24 Months" }, "enrollment_count": 303, "start_date": "2016-10", "completion_date": "2020-03-24", "has_results": true, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 11, "location_summary": "San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02789176" }, { "nct_id": "NCT01803867", "title": "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "rHIgM22", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acorda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2013-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 17, "location_summary": "Long Beach, California • Palo Alto, California • Sacramento, California + 13 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01803867" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT02429375", "title": "Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Mocetinostat Plus Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-04-22", "completion_date": "2021-02-17", "has_results": true, "last_update_posted_date": "2022-05-12", "last_synced_at": "2026-09-04T11:34:50.263Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429375" } ] }